For most patients with drug-refractory epilepsy who are eligible for surgical treatment, their outcomes end up better than continuing on medical therapy in most cases, two new studies suggested.

In the fist study, which was based on published data from various sources, researchers led by Iván Sánchez Fernández, MD, of Boston Children’s Hospital calculated that the average 10-year-old undergoing surgery for drug-refractory temporal lobe epilepsy has a life expectancy of 55.2 additional years — versus 49.3 years for those managed with drug therapy.

READ FULL ARTICLE Curated publisher From Medical Page Today